Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul;12(7):877-9.
doi: 10.1586/era.12.71.

New Frontiers in Therapeutic Resistance in Cancer

Affiliations

New Frontiers in Therapeutic Resistance in Cancer

Andrea Sartore-Bianchi et al. Expert Rev Anticancer Ther. .

Abstract

Despite advances in personalized medicine and targeted therapies, therapeutic resistance remains a persistent dilemma encountered by clinicians, scientists and patients. In this article we summarize the highlights of the third Quebec Conference on Therapeutic Resistance in Cancer. This unique meeting provided researchers and clinicians with insights into: intrinsic and acquired resistance; tumor heterogeneity; complexities of biomarker-driven trials; challenges of 'omics data analysis; and models of clinical applications of personalized medicine. Emphasized throughout the conference was the importance of collaborations - between industry and academia, and between basic researchers and clinicians - so that therapeutic resistance can be studied where it matters most, in patients.

Similar articles

See all similar articles

Cited by 2 articles

Publication types

Substances

Feedback